Silence Therapeutics plc
For the period ended Sep 30, 2025. Filed Nov 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 6, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
8. Benefit from R&D credit
An addi tional $2.6 million was recognized in respect of research and development tax credits in the three months ended September 30, 2025 (three months ended September 30, 2024: $4.5 million).
An additional $7.6 million was recognizedin respect of research and development tax credits in the nine months ended September 30, 2025 (nine months ended September 30, 2024: $9.7 million).
The current asset at September 30, 2025 was $22.2 million, comprised of $7.6 million in respect of research and development activities for the nine months ended September 30, 2025 and $24.4 million in respect of the year ended December 31, 2024. In the nine months ended September 30, 2025, the Group received $11.0 million related to the receipt of the 2023 claim for past research and development tax credits.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.